Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Spero Therapeutics Inc.

    NASDAQ: SPRO · Real-Time Price · USD
    2.86
    0.03 (1.06%)
    At close: Jun 16, 2025, 3:59 PM
    2.85
    -0.35%
    Pre-market: Jun 17, 2025, 05:06 AM EDT

    Spero Therapeutics Statistics

    Share Statistics

    Spero Therapeutics has 55.91M shares outstanding. The number of shares has increased by 0.98% in one year.

    Shares Outstanding

    n/a
    		 55.91M

    Shares Change (YoY)

    n/a
    		 0.98%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 28.97%

    Shares Floating

    n/a
    		 37.37M

    Failed to Deliver (FTD) Shares

    n/a
    		 4

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 3.48M, so 6.22% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 3.48M

    Short % of Shares Out

    n/a
    		 6.22%

    Short % of Float

    n/a
    		 7.6%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -0.81 and the forward PE ratio is -1.74. Spero Therapeutics's PEG ratio is 0.

    PE Ratio

    n/a
    		 -0.81

    Forward PE

    n/a
    		 -1.74

    PS Ratio

    n/a
    		 2.03

    Forward PS

    n/a
    		 1.5

    PB Ratio

    n/a
    		 1.21

    P/FCF Ratio

    n/a
    		 -2.37

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Spero Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.19, with a Debt / Equity ratio of 0.09.

    Current Ratio

    n/a
    		 2.19

    Quick Ratio

    n/a
    		 2.19

    Debt / Equity

    n/a
    		 0.09

    Debt / EBITDA

    n/a
    		 -0.06

    Debt / FCF

    n/a
    		 -0.18

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $856,125

    Profits Per Employee

    n/a
    		 $-2,142,687.5

    Employee Count

    n/a
    		 32

    Asset Turnover

    n/a
    		 0.25

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 123.44% in the last 52 weeks. The beta is 1.31, so Spero Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.31

    52-Week Price Change

    n/a
    		 123.44%

    50-Day Moving Average

    n/a
    		 1.22

    200-Day Moving Average

    n/a
    		 1.1

    Relative Strength Index (RSI)

    n/a
    		 77.57

    Average Volume (20 Days)

    n/a
    		 3,970,461

    Income Statement

    In the last 12 months, Spero Therapeutics had revenue of 27.4M and earned -68.57M in profits. Earnings per share was -1.27.

    Revenue

    n/a
    		 27.4M

    Gross Profit

    n/a
    		 27.39M

    Operating Income

    n/a
    		 -73.36M

    Net Income

    n/a
    		 -68.57M

    EBITDA

    n/a
    		 -73.36M

    EBIT

    n/a
    		 -72.48M

    Earnings Per Share (EPS)

    n/a
    		 -1.27
    Full Income Statement

    Balance Sheet

    The company has 52.89M in cash and 4.3M in debt, giving a net cash position of 48.59M.

    Cash & Cash Equivalents

    n/a
    		 52.89M

    Total Debt

    n/a
    		 4.3M

    Net Cash

    n/a
    		 48.59M

    Retained Earnings

    n/a
    		 -459.64M

    Total Assets

    n/a
    		 77.71M

    Working Capital

    n/a
    		 45.56M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -23.44M and capital expenditures 0, giving a free cash flow of -23.44M.

    Operating Cash Flow

    n/a
    		 -23.44M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -23.44M

    FCF Per Share

    n/a
    		 -0.43
    Full Cash Flow Statement

    Margins

    Gross margin is 99.99%, with operating and profit margins of -267.78% and -250.28%.

    Gross Margin

    n/a
    		 99.99%

    Operating Margin

    n/a
    		 -267.78%

    Pretax Margin

    n/a
    		 -250.28%

    Profit Margin

    n/a
    		 -250.28%

    EBITDA Margin

    n/a
    		 -267.78%

    EBIT Margin

    n/a
    		 -267.78%

    FCF Margin

    n/a
    		 -85.57%

    Dividends & Yields

    SPRO pays an annual dividend of $0.07, which amounts to a dividend yield of 0.52%.

    Dividend Per Share

    n/a
    		 $0.07

    Dividend Yield

    n/a
    		 0.52%

    Dividend Growth (YoY)

    n/a
    		 0%

    Payout Ratio

    n/a
    		 -5.86%

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for SPRO is $5, which is 74.8% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $5

    Price Target Difference

    n/a
    		 74.8%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 4
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -8.86

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist